Cyproheptadine inhibits in vitro and in vivo lung metastasis and drives metabolic rewiring
Molecular Biology Reports · 2024
DOI: 10.1007/s11033-024-10033-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Ahmad Shannar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ, 08…. Hauptthemen laut MEDLINE: Lung Neoplasms, Cyproheptadine, Carcinoma, Non-Small-Cell Lung, Cell Movement. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Center for Complementary and Integrative Health, National Institute of Environmental Health Sciences.
Abstract (Originalsprache)
Background
Non-small cell lung cancer (NSCLC) accounts for 81% of lung cancer cases, among which over 47% presented with distant metastasis at the time of diagnosis. Despite the introduction of targeted therapy and immunotherapy, enhancing the survival rate and overcoming the development of resistance remain a big challenge. Thus, it is crucial to find potential new therapeutics and targets that can mitigate lung metastasis and investigate its effects on biomarkers, such as cellular metabolomics. In the current study, we investigated the role of cyproheptadine (CPH), an FDA-approved anti-histamine drug in lung metastasis in vitro and in vivo. Methods and results CPH showed potent cytotoxicity on different lung cancer cell lines in vitro. Moreover, CPH decreased invasion and migration of LLC1 and A549 cells in Matrigel invasion transwell and plate scratch assays. The in vivo LLC1 syngeneic lung cancer model found decreased number of metastatic nodules on the surface of lungs of Setd7 KO mice compared to SETD7 WT. CPH treatment resulted in decreased growth of LLC1 subcutaneous tumors compared to untreated SETD7 WT. Finally, metabolomic study of tumor tissues showed rewiring of metabolomic pathways and downregulation of amino acids, such as arginine, serine, and glycine) in Setd7 KO and WT treated with CPH compared to untreated Setd7 WT mice.
Conclusion
These findings identify CPH as a potential therapeutic agent to block metastasis in advanced NSCLC and suggest SETD7 as a potential target for the prevention of lung metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ, 08854, USA.
- Graduate Program in Pharmaceutical Sciences, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
- Department of Medical Genetics, University of British Columbia, Vancouver, BC, V6T 1Z1, Canada.
- Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ, 08854, USA. KongT@pharmacy.rutgers.edu.
Förderung
- National Center for Complementary and Integrative Health
- National Institute of Environmental Health Sciences
Zitieren
APA
Shannar, A., Sarwar, M. S., Dave, P. D., Chou, P. J., Peter, R. M., Xu, J., Pan, Y., Rossi, F., & Kong, A. N. (2024). Cyproheptadine inhibits in vitro and in vivo lung metastasis and drives metabolic rewiring. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-10033-6
Vancouver
Shannar A, Sarwar MS, Dave PD, Chou PJ, Peter RM, Xu J, et al. Cyproheptadine inhibits in vitro and in vivo lung metastasis and drives metabolic rewiring. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-10033-6
BibTeX
@article{Shannar2024,
author = {Shannar, Ahmad and Sarwar, Md Shahid and Dave, Parv Dushyant and Chou, PoChung Jordan and Peter, Rebecca Mary and Xu, Jiawei and Pan, Yuxin and Rossi, Fabio and Kong, Ah-Ng},
title = {Cyproheptadine inhibits in vitro and in vivo lung metastasis and drives metabolic rewiring},
journal = {Molecular Biology Reports},
year = {2024},
doi = {10.1007/s11033-024-10033-6}
}
EUVIMED